Related Experiment Video
Updated: May 16, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Toxicological considerations of acetylcholinesterase reactivators
Victor Voicu1, Flavian Ştefan Rădulescu, Andrei Medvedovici
1University of Medicine and Pharmacy Carol Davila, Department of Clinical Pharmacology, Toxicology and Psychopharmacology, Bucharest, Romania.
Introduction:
The more or less systematic studies on the specific activity of oximes as reactivators of acetylcholinesterase (AChE) inhibited by organophosphorus (OP) compounds provide a panoramic image of their pharmacological and toxicological profiles. Established structure-activity relationships are still unable to adequately predict their antidotal efficacy. However, the in vivo behavior of oximes is a direct consequence of their physico-chemical properties, considerably limiting the passive transport across the biological barriers.
Areas Covered:
This paper discusses the efficacy of oximes from a biokinetic perspective. The non-homogenous distribution of oximes versus OP in tissues was considered and correlated with the highly variable AChE reactivation at both peripheral and central levels. The acute toxicity and formation of highly toxic phosphylated oximes are presented as possible sources for reduced therapeutic efficacy.
Expert Opinion:
Biokinetic of oximes is 'structure dependent', with variable, tissue-specific distribution and activity. The existing knowledge does not allow to state true limits for a minimum extent of AChE reactivation in different tissues granting the survival of intoxicated organisms. An increased penetration of biological barriers is not automatically equivalent to a high extent of reactivation or antidotal efficacy and most probably, induces significant risks because of the intrinsic toxicity of the oxime.
More Related Videos
14:39Cholinergic Ligand–dependent Modulation of Oxidative Phosphorylation Coupling in Digitonin-permeabilized BE(2)-C Neuroblastoma Cells
Published on: April 28, 2026
07:09Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
Published on: September 8, 2011
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
Direct-Acting Cholinergic Agonists: Pharmacokinetics